Key Transaction Details
The Board of Directors of Novartis India Limited at its meeting held on September 7, 2026 approved the acquisition of trademarks 'Minipress' and 'Minipres' registered in India and certain related intellectual property rights from Pfizer Inc. USA and Pfizer Products Inc. USA.
Financial Consideration
The total aggregate consideration for the transaction is INR 1250,00,10,000 (One Thousand Two Hundred Fifty Crores and Ten Thousand only).
Execution of Agreements
On September 7, 2026, the Company executed an asset purchase agreement and trademark assignment deeds with Pfizer Inc. USA and Pfizer Products Inc. USA in connection with the transaction. The signing and closing of the transaction under the asset purchase agreement occurred simultaneously.
Product and Market Details
As per IQVIA MAT July'26 data, Minipress XL recorded revenue of INR 228.6 crores and has been growing at a CAGR of 6.3% for past four years while the category has been growing at 9% CAGR for past four years. Minipress XL (containing prazosin) is primarily indicated in India for treating hypertension (high blood pressure) and managing the urinary symptoms of benign prostatic hyperplasia (BPH).
Relationship Disclosure
The counterparties (Pfizer Inc. USA and Pfizer Products Inc. USA) are not related to promoter/promoter group/group companies in any manner. This is not a related party transaction.
Additional Terms
No shareholding exists in the entities with whom the agreement is executed. No significant terms like special rights, appointment of directors, first right to share subscription, or rights to restrict capital structure changes apply to this transaction.